Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: French National Agency for Research on AIDS and Viral Hepatitis to ANRS, Emerging Infectious Diseases
    • Study sites: 0 to 1
    • Publications: 1 to 2
    v2
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The combination of two nucleoside analogues and one protease inhibitor is a highly active antiretroviral therapy (HAART) in HIV infected adults. In those with an undetectable viral load, a once daily combination of FTC, ddI, efavirenz would be easier to take, with less side effects and the same efficacy. The aim of the study was to evaluate if the once daily combination presents the same efficacy than the HAART therapy with less side effects and a better adherence.
Trial Details
NCT Number NCT00196612
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: Triangle Pharmaceuticals, Gilead Sciences, Bristol-Myers Squibb, Dupont Applied Biosciences
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 350 participants
Start Date
Study Completion (estimated)
Updated on ClinicalTrials.gov